or Try an Advanced Search...

    ETF Components for SBIO - ALPS Medical Breakthroughs ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    KRYS C -0.03 3.94
    ALKS D 0.17 3.10
    MRUS C -0.26 3.01
    RNA C -4.10 2.93
    IMVT F -1.21 2.87
    CRNX D -2.94 2.59
    CORT C -3.36 2.52
    DNLI C -2.02 2.47
    FOLD F -0.41 2.22
    ACLX B 2.76 2.18
    XENE F -1.20 2.13
    ACAD D -1.58 2.04
    PTCT D 2.01 2.01
    GERN C 4.56 1.99
    IDYA F -1.28 1.96
    AGIO C -0.07 1.87
    CLDX D -2.97 1.87
    VCEL D -0.36 1.72
    NTLA F 3.61 1.69
    CGON F -1.56 1.52
    VERA D -0.11 1.44
    PTGX B -0.26 1.41
    ZLAB F -0.86 1.35
    ARVN F -3.82 1.33
    SNDX D -2.81 1.30
    MORF C 1.76 1.29
    GLPG F -1.78 1.25
    IMCR F 3.51 1.24
    KROS F -1.49 1.23
    EWTX C -0.54 1.23
    AKRO D -2.01 1.22
    MIRM B 0.59 1.18
    KURA D -2.53 1.18
    MNKD C 0.00 1.09
    RCUS F -1.98 1.04
    BCRX B -2.14 0.95
    VRNA B 1.62 0.94
    DAWN F 0.30 0.91
    XNCR F 1.92 0.89
    IRON C 6.75 0.83
    PRTA F -1.57 0.83
    FDMT D 1.31 0.82
    IRWD F -1.77 0.74
    PHVS F 0.89 0.73
    TARS D 5.01 0.72
    LQDA D 1.10 0.71
    VRDN F 0.74 0.62
    AUPH D 0.74 0.61
    COGT C 1.46 0.61
    SPRY C 4.97 0.59
    LBPH B 3.81 0.57
    ETNB F -1.58 0.56
    ANAB B 4.01 0.51
    ARCT F 2.09 0.50
    HLVX D -1.26 0.50
    PLRX F -0.19 0.49
    GHRS D 1.18 0.47
    OLMA D 2.50 0.47
    URGN C -0.86 0.46
    ERAS C -6.03 0.45
    FLGT F -0.25 0.45
    MLYS D 0.50 0.43
    CELC B 0.74 0.43
    ITOS D 2.35 0.42
    YMAB D 0.09 0.41
    APLT D 0.69 0.40
    SVRA D 0.70 0.40
    REPL D -3.35 0.39
    ALLO F -3.70 0.38
    ALT F -2.08 0.34
    ALEC F 1.61 0.33
    ANNX D 5.04 0.33
    TBPH F 2.28 0.31
    CMPS D 5.20 0.31
    ACIU C -1.55 0.30
    FULC F 0.90 0.29
    AURA F -3.50 0.27
    AVXL C -0.24 0.27
    VNDA C 1.71 0.26
    ZNTL F -2.52 0.23
    INZY D 1.58 0.21
    ENTA C -2.30 0.20
    STRO F -2.70 0.18
    ALDX F -1.54 0.15

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Medicine Biotechnology Cancer Biology Clinical Medicine Life Sciences Organ Systems Disease Clinical Development Immunology Antibodies Autoimmune Disease Immune System Chemical Compounds Monoclonal Antibodies Neurological Disorders Rare Diseases Solid Tumors Alcohol
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities

    Recent News for ALPS Medical Breakthroughs ETF & its Holdings

    Date Stock Title
    Jul 3 LBPH Top 3 Health Care Stocks That May Crash This Quarter
    Jul 3 KURA Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
    Jul 3 RNA Avidity’s FSHD drug del-brax shows promise in Phase I/II trial
    Jul 3 NTLA Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
    Jul 2 INZY Inozyme gets Fast Track status for candidate for rare calcification condition
    Jul 2 VCEL Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio?
    Jul 2 XENE Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
    Jul 2 LBPH Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
    Jul 2 INZY Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
    Jul 2 NTLA 3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
    Jul 2 ALT Altimmune to Participate at Leerink Partners Therapeutics Forum
    Jul 2 YMAB MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
    Jul 1 ARCT Arcturus to file IND for phase 2 study for cystic fibrosis candidate
    Jul 1 YMAB Y-mAbs names Peter Pfreundschuh as CFO
    Jul 1 YMAB Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
    Jul 1 MRUS Sector Update: Health Care Stocks Retreat Late Afternoon
    Jul 1 ARCT Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
    Jul 1 LBPH Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
    Jul 1 ALLO Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
    Jul 1 VERA Vera Therapeutics appoints David Johnson as COO
    The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
    Exchange Traded Fund ETF Index Fund Biotechnology Pharmaceutical Passive Management
    Back to the Main SBIO Page...